Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MTOR | P42345 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844421 | 0.80 | TRPV1 (0.47) | MAOBAPPPTPN1BACE1MAPT | |
| SCHEMBL4740706 | 0.79 | MAPT (0.32) | MAOBAPPPTPN1BACE1MAPT | |
| SCHEMBL797945 | 0.78 | MAPT (0.43) | PPARGPPARAMAPTMEN1KMT2A | |
| SCHEMBL797946 | 0.78 | MAPT (0.43) | PPARGPPARAMAPTMEN1KMT2A | |
| SCHEMBL11021671 | 0.73 | TRPV1 (0.53) | MAPTADRB2ADRB1TDP1ADRB3 | |
| SCHEMBL3790805 | 0.72 | MAOB (0.41) | PPARGPPARAMAOBAPPPTPN1 | |
| SCHEMBL11022644 | 0.72 | TRPV1 (0.43) | MAPTADRB2ADRB1TDP1ADRB3 | |
| SCHEMBL11022643 | 0.72 | TRPV1 (0.43) | MAPTADRB2ADRB1TDP1ADRB3 | |
| SCHEMBL10783130 | 0.72 | TRPV1 (0.43) | MAPTADRB2ADRB1TDP1ADRB3 | |
| SCHEMBL10780294 | 0.72 | TRPV1 (0.54) | MAPTADRB2ADRB1TDP1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4302836-A1 | ANTIBODIES AGAINST SNAKE TOXINS CAUSING MUSCLE AND/OR TISSUE DAMAGE | Danmarks Tekniske Universitet (DK) | 2024-01-10 | — | — | EP | claimed |
| US-11344506-B2 | Rapidly disintegrating oral dissolvable film | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2022-05-31 | — | — | US | claimed |
| EP-1578433-B1 | USE OF POTHOMORPHE UMBELLATA EXTRACT AND GEL COMPOSITION ON BASIS OF POTHOMORPHE UMBELLATA EXTRACT | FUNDACAO DE AMPARO A PESQUISA (BR) | 2010-08-18 | — | — | EP | claimed |
| WO-2008095273-A2 | METHOD FOR OBTENTION OF THE ENZYMATIC EXTRACT OF POTOMORPHE UMBELLATA | UNIVERSIDADE ESTADUAL JÚLIO DE MESQUITA FILHO - UNESP (BR) | 2008-08-14 | — | — | WO | claimed |
| US-20060062858-A1 | Use of pothomorphe umbellata extract, composition on basis of pothomorphe umbellata extract and method of application of the pothomorphe umbellata extract | UNIVERSIDADE DE SAO PAULO - USP (BR) | 2006-03-23 | — | — | US | claimed |
| EP-1578433-A1 | USE OF POTHOMORPHE UMBELLATA EXTRACT, COMPOSITION ON BASIS OF POTHOMORPHE UMBELLATA EXTRACT AND METHOD OF APPLICATION OF THE POTHOMORPHE UMBELLATA EXTRACT | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP (BR) | 2005-09-28 | — | — | EP | claimed |
| WO-2004026323-A1 | USE OF POTHOMORPHE UMBELLATA EXTRACT, COMPOSITION ON BASIS OF POTHOMORPHE UMBELLATA EXTRACT AND METHOD OF APPLICATION OF THE POTHOMORPHE UMBELLATA EXTRACT | FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP (BR) | 2004-04-01 | — | — | WO | claimed |
| US-20260060924-A1 | SEMI-SOLID ORAL DOSAGE FORM WITH ENCAPSULATED ACTIVE INGREDIENT | CONCEPT MATRIX SOLUTIONS (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025040765-A1 | IN VIVO NEUTRALIZATION OF CORAL SNAKE VENOMS WITH AN OLIGOCLONAL NANOBODY MIXTURE | DANMARKS TEKNISKE UNIVERSITET (DK) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-4302836-A1 | ANTIBODIES AGAINST SNAKE TOXINS CAUSING MUSCLE AND/OR TISSUE DAMAGE | Danmarks Tekniske Universitet (DK) | 2024-01-10 | — | — | EP | disclosed |
| US-11857557-B2 | Oral dissolvable film containing vitamin D3 | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2024-01-02 | — | — | US | disclosed |
| WO-2023209212-A1 | NEUTRALISATION OF α-NEUROTOXINS USING HUMAN RECOMBINANT IGG ANTIBODIES | DANMARKS TEKNISKE UNIVERSITET (DK) | 2023-11-02 | — | — | WO | disclosed |
| WO-2009082795-A1 | DERIVATIVES OF 4-NEROLIDYLCATECHOL, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESS FOR PRODUCING THE SAME | INSTITUTO NACIONAL DE PESQUISA DA AMAZÔNIA - INPA (BR) | 2009-07-09 | — | — | WO | disclosed |
| WO-2008095273-A3 | METHOD FOR OBTENTION OF THE ENZYMATIC EXTRACT OF POTOMORPHE UMBELLATA | UNIV ESTADUAL JULIO DE MESQUIT (BR) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008095273-A2 | METHOD FOR OBTENTION OF THE ENZYMATIC EXTRACT OF POTOMORPHE UMBELLATA | UNIVERSIDADE ESTADUAL JÚLIO DE MESQUITA FILHO - UNESP (BR) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008095273-A2 | METHOD FOR OBTENTION OF THE ENZYMATIC EXTRACT OF POTOMORPHE UMBELLATA | UNIVERSIDADE ESTADUAL JÚLIO DE MESQUITA FILHO - UNESP (BR) | 2008-08-14 | — | — | WO | disclosed |
| US-20060062858-A1 | Use of pothomorphe umbellata extract, composition on basis of pothomorphe umbellata extract and method of application of the pothomorphe umbellata extract | UNIVERSIDADE DE SAO PAULO - USP (BR) | 2006-03-23 | — | — | US | disclosed |
| EP-1578433-A1 | USE OF POTHOMORPHE UMBELLATA EXTRACT, COMPOSITION ON BASIS OF POTHOMORPHE UMBELLATA EXTRACT AND METHOD OF APPLICATION OF THE POTHOMORPHE UMBELLATA EXTRACT | Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP (BR) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004026323-A1 | USE OF POTHOMORPHE UMBELLATA EXTRACT, COMPOSITION ON BASIS OF POTHOMORPHE UMBELLATA EXTRACT AND METHOD OF APPLICATION OF THE POTHOMORPHE UMBELLATA EXTRACT | FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESP (BR) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060924-A1 | SEMI-SOLID ORAL DOSAGE FORM WITH ENCAPSULATED ACTIVE INGREDIENT | ALPI, S100P, SI | PPARG 1596/4885PPARA 3304/4885MAOB 2202/4885 |
| US-11857557-B2 | Oral dissolvable film containing vitamin D3 | CYP24A1, CYP2R1, VDR | PPARG 3215/4885PPARA 3275/4885MAOB 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.